Abstract

Antimicrobial resistance (AMR) poses a threat to public health. Clinical microbiology laboratories typically rely on culturing bacteria for antimicrobial-susceptibility testing (AST). As the implementation costs and technical barriers fall, whole-genome sequencing (WGS) has emerged as a ‘one-stop’ test for epidemiological and predictive AST results. Few published comparisons exist for the myriad analytical pipelines used for predicting AMR. To address this, we performed an inter-laboratory study providing sets of participating researchers with identical short-read WGS data from clinical isolates, allowing us to assess the reproducibility of the bioinformatic prediction of AMR between participants, and identify problem cases and factors that lead to discordant results. We produced ten WGS datasets of varying quality from cultured carbapenem-resistant organisms obtained from clinical samples sequenced on either an Illumina NextSeq or HiSeq instrument. Nine participating teams (‘participants’) were provided these sequence data without any other contextual information. Each participant used their choice of pipeline to determine the species, the presence of resistance-associated genes, and to predict susceptibility or resistance to amikacin, gentamicin, ciprofloxacin and cefotaxime. We found participants predicted different numbers of AMR-associated genes and different gene variants from the same clinical samples. The quality of the sequence data, choice of bioinformatic pipeline and interpretation of the results all contributed to discordance between participants. Although much of the inaccurate gene variant annotation did not affect genotypic resistance predictions, we observed low specificity when compared to phenotypic AST results, but this improved in samples with higher read depths. Had the results been used to predict AST and guide treatment, a different antibiotic would have been recommended for each isolate by at least one participant. These challenges, at the final analytical stage of using WGS to predict AMR, suggest the need for refinements when using this technology in clinical settings. Comprehensive public resistance sequence databases, full recommendations on sequence data quality and standardization in the comparisons between genotype and resistance phenotypes will all play a fundamental role in the successful implementation of AST prediction using WGS in clinical microbiology laboratories.

Highlights

  • Antimicrobial resistance (AMR) is a major, global, public-­ health threat, with projections of up to 10 million deaths per annum by 2050 [1]

  • Phenotypic antimicrobial-­ susceptibility testing (AST) was performed at University Hospital Galway (UHG) and Great Ormond Street Hospital (GOSH) using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) disc diffusion method and meropenem, ertapenem, cefotaxime, amikacin, gentamicin and ciprofloxacin

  • Lab_1a, Lab_2, Lab_3 and Lab_5 all repeatedly reported the highest number of genes in each sample and all used the Comprehensive Antibiotic Resistance Database as their reference database. This is due to card including many sequences from loosely AMR-­ associated efflux pump genes that are not found in the other databases

Read more

Summary

Introduction

Antimicrobial resistance (AMR) is a major, global, public-­ health threat, with projections of up to 10 million deaths per annum by 2050 [1]. The World Health Organization’s 2015 Global Action Plan on AMR identified diagnostics as a priority area for combating resistance [2]. Most diagnostic AMR testing is phenotypic antimicrobial-­ susceptibility testing (AST) and is based on principles dating back to the early 20th century [3]. Molecular testing has facilitated the implementation of PCR assays that target key AMR mutations and genes [4, 5]. There remains an unmet need for truly rapid point-­of-­care AST [6, 7].

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call